利拉鲁肽联合丹蒌片对冠心病合并2型糖尿病患者的影响  

Effect of Liraglutide and Danlou Tablet on Patients with Coronary Heart Disease and Type 2 Diabetes

作　　者：颜伟鹏 孙玉芹[1] YAN Weipeng;SUN Yuqin(Affiliated Hospital of Beihua University,Jilin 132011,China)

机构地区：[1]北华大学附属医院,吉林吉林132011

出　　处：《北华大学学报（自然科学版）》2022年第5期630-633,共4页Journal of Beihua University（Natural Science）

基　　金：吉林市科技发展计划项目(201900982).

摘　　要：目的探讨利拉鲁肽联合应用丹蒌片对冠心病合并2型糖尿病患者的干预作用.方法将120例冠心病伴2型糖尿病患者随机分为利拉鲁肽组、丹蒌片组和联合用药组,每组40例.比较3组治疗前后总胆固醇(Total cholesterol,TC)、甘油三酯(Triglyeride,TG)、低密度脂蛋白(Low density lipoprotein,LDL)、高密度脂蛋白(High density lipoprotein,HDL)、肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)、白细胞介素-6(Interleukin-6,IL-6)水平及颈动脉斑块变化情况.结果3组治疗前上述指标比较差异均无统计学意义(P>0.05).与治疗前比较,治疗后丹蒌片组和利拉鲁肽组患者TC、TG、LDL-C、TNF-α、IL-6、颈动脉斑块直径以及IMT数值均有所下降(P<0.05),同时HDL-C水平较治疗前升高(P<0.05);利拉鲁肽和丹蒌片联合应用后,患者HDL-C水平高于单一用药组(P<0.05),其他指标均低于单一用药组(P<0.05).结论利拉鲁肽与丹蒌片能够降低冠心病合并2型糖尿病患者的血脂水平,抑制促炎细胞因子的产生,进而减轻炎性细胞对心脏的损伤,稳定颈动脉斑块,从而抑制疾病发展,且联合用药强于单一用药,安全性较高.Objective To explore the effect of Liraglutide combined with Danlou tablet on coronary heart disease combined with type 2 diabetes.Method 120 patients with coronary heart disease complicated with type 2 diabetes were randomly divided into Liraglutide group,Danlou tablet group and combination group,40 cases in each group.The levels of total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDH)and high density lipoprotein(HDL),tumor necrosis factor-α(TNF-α),Interleukin-6(IL-6)and carotid plaque were compared before and after treatment among the three groups.Results There was no difference in the above indexes among the three groups before treatment(P>0.05).Compared with before treatment,TC,TG,LDL-C,TNF-α,IL-6,carotid plaque diameter and IMT were decreased in Danlou tablet group and Liraglutide group(P<0.05),and the level of HDL-C was increased(P<0.05).The level of HDL-C in combination with Liraglutide and Danlou tablet was higher than that in single drug group(P<0.05),and other indicators were lower than that in single drug group(P<0.05).Conclusion Liraglutide and Danlou tablet could reduce the blood lipid level,inhibit the production of proinflammatory factors,reduce inflammatory damage,stabilize carotid plaque and inhibit the development of coronary heart disease with type 2 diabetes.The combination of Liraglutide and Danlou tablet was better than single drug,and had higher safety.

关 键 词：利拉鲁肽 丹蒌片 冠心病 颈动脉粥样硬化斑块 

分 类 号：R587[医药卫生—内分泌]